REGENERON PHARMACEUTICALS,INC. (NASDAQ:REGN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive
Agreement.
On February2, 2017, Regeneron Pharmaceuticals,Inc.
(Regeneron or the Company) and the Subsidiary
Borrowers (as defined below) entered into the Consent and
Amendment No.1 Memorandum (the Amendment) relating to the
Credit Agreement, dated as of March19, 2015 (as amended, the
Credit Agreement), by and among the Company, as a borrower
and guarantor; Regeneron Healthcare Solutions,Inc., Regeneron
Genetics Center LLC, Regeneron International Unlimited Company,
Regeneron Ireland Holdings Unlimited Company, Regeneron Ireland
Unlimited Company, and Regeneron Capital International B.V., as
subsidiary borrowers (collectively, the Subsidiary
Borrowers); JPMorgan Chase Bank, N.A., as administrative
agent; and the lenders and other financial institutions party
thereto from time to time.
to the Amendment, the requisite lenders under the Credit
Agreement have agreed, among other things, to (a)amend the Credit
Agreement in connection with the proposed acquisition of the
Companys existing corporate headquarters and other rentable area
consisting of approximately 150 acres of predominately office
buildings and laboratory space located in the towns of Mount
Pleasant and Greenburgh, NY (the Facility) and the related
lease financing contemplated by the Company; and (b)provide that
such lease financing and certain other lease or similar
arrangements shall not constitute Indebtedness or Capital Lease
Obligations for purposes of the Credit Agreement, including for
purposes of calculating the Companys total leverage ratio
thereunder. The Companys agreement to purchase the Facility was
previously reported in its Current Report on Form8-K filed with
the United States Securities and Exchange Commission on
December30, 2016.
As of the date of this report, no amounts were outstanding under
the Credit Agreement.
The foregoing description of the Amendment is qualified in its
entirety by reference to the full text of the Amendment, a copy
of which is attached as Exhibit10.1 hereto and is incorporated
herein by reference.
Item 9.01. Financial Statements and
Exhibits.
(d)Exhibits.
|
10.1 |
Consent and Amendment No.1 Memorandum, dated as of |
About REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909. REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) Recent Trading Information
REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) closed its last trading session up +3.74 at 362.00 with 750,326 shares trading hands.
